During the preclinical stage of AD, before symptom onset, the pathophysiological course of the disease is characterized by first the formation of amyloid plaques and later p-tau protein aggregates, which accumulate in the brain and disrupt normal neuronal function (Sperling et al., 2011). The gene discussed is MAPT; the disease is amyloidosis.